Company news

Skye Bioscience, Inc. news in 2025

Skye Bioscience, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Skye Bioscience to Participate in Upcoming Investment Conferences

November 24, 2025

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

November 10, 2025

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

November 5, 2025

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

November 5, 2025

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

October 6, 2025

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

September 19, 2025

Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

September 4, 2025

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

September 2, 2025

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

August 27, 2025

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

August 21, 2025

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

August 7, 2025

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

July 30, 2025

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

June 23, 2025

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

June 17, 2025

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

May 7, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

April 29, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

April 15, 2025

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

April 14, 2025

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 20, 2025

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

March 14, 2025

Skye Bioscience to Participate in SXSW Session on Obesity

February 24, 2025

Skye Bioscience to Present at TD Cowen Health Care Conference

February 20, 2025

Skye Bioscience Announces Participation in February Conferences

February 3, 2025

Skye Bioscience Provides 2025 Look Ahead and Year in Review

January 12, 2025

Calls in 2025

Decks in 2025